The Experts below are selected from a list of 96 Experts worldwide ranked by ideXlab platform
Lee F Allen - One of the best experts on this subject based on the ideXlab platform.
-
a phase iii randomized open label trial of ferumoxytol compared with Iron sucrose for the treatment of Iron deficiency anemia in patients with a history of unsatisfactory oral Iron therapy
American Journal of Hematology, 2014Co-Authors: David Hetzel, William Strauss, Kristine Bernard, Audrone Urboniene, Lee F AllenAbstract:Iron deficiency anemia (IDA) is the most common form of anemia worldwide. Although oral Iron is used as first-line treatment, many patients are unresponsive to or cannot take oral Iron. This Phase III, open-label, non-inferiority study compared the efficacy and safety of ferumoxytol, a rapid, injectable intravenous (IV) Iron Product with low immunological reactivity and minimal detectable free Iron, with IV Iron sucrose in adults with IDA of any cause. Patients (N = 605) were randomized 2:1 to receive ferumoxytol (n = 406, two doses of 510 mg 5 ± 3 days apart) or Iron sucrose (n = 199, five doses of 200 mg on five nonconsecutive days over 14 days) and followed for 5 weeks. Ferumoxytol demonstrated noninferiority to Iron sucrose at the primary endpoint, the proportion of patients achieving a hemoglobin increase of ≥2 g dL−1 at any time from Baseline to Week 5 (ferumoxytol, 84.0% [n = 406] vs. Iron sucrose, 81.4% [n = 199]), with a noninferiority margin of 15%. Ferumoxytol was superior to Iron sucrose (2.7 g dL−1 vs. 2.4 g dL−1) in the mean change in hemoglobin from Baseline to Week 5 (the alternative preplanned primary endpoint) with P = 0.0124. Transferrin saturation, quality-of-life measures, and safety outcomes were similar between the two treatment groups. Overall, ferumoxytol demonstrated comparable safety and efficacy to Iron sucrose, suggesting that ferumoxytol may be a useful treatment option for patients with IDA in whom oral Iron was unsatisfactory or could not be used. Am. J. Hematol. 89:646–650, 2014. © 2014 Wiley Periodicals, Inc.
Andrew R. Barron - One of the best experts on this subject based on the ideXlab platform.
-
pyrometallurgical removal of zinc from basic oxygen steelmaking dust a review of best available technology
Resources Conservation and Recycling, 2020Co-Authors: Daniel J C Stewart, Andrew R. BarronAbstract:Abstract Approximately 20 kg of dust and sludges are produced per ton of liquid steel produced via the blast furnaces (BF)/basic oxygen furnace (BOF) Production route. Many of these dusts are recycled through the sinter plant or blast furnace route without issue, but high zinc content dusts are routinely landfilled. Hydrometallurgical techniques, such as alkaline leaching, that are often utilized to remove zinc from electric arc furnace dusts are inappropriate for recovery of material from BOS dust due to the lower zinc concentration present and extra post-processing steps to utilize the separated Iron Product. Pyrometallurgical treatment through a rotary hearth furnace (RHF), in processes such as FASTMET®, can currently be considered as the most commercially attractive option for the processing and recovery of Iron and zinc units when employed as part of an integrated steelworks. The crude zinc oxide produced is suitable for sale to zinc smelters, and the direct reduced Iron produced provides process benefits through use, such as reduced blast furnace coking rates and increased Productivity. The advantages and disadvantages of variations and alternatives are reviewed with regard to future developments.
Brian J G Pereira - One of the best experts on this subject based on the ideXlab platform.
-
ferumoxytol as an intravenous Iron replacement therapy in hemodialysis patients
Clinical Journal of The American Society of Nephrology, 2009Co-Authors: Robert Provenzano, Brigitte Schiller, Madhumathi Rao, Daniel W Coyne, Louis Brenner, Brian J G PereiraAbstract:Background and objectives: Intravenous Iron is a key component of anemia management for chronic kidney disease (CKD). Ferumoxytol is a unique intravenous Iron Product that can be administered as a rapid injection in doses up to 510 mg. Design, setting, participants, & measurements: This was a randomized, open-label, controlled, multicenter Phase 3 trial to evaluate the safety and efficacy of intravenous ferumoxytol compared with oral Iron. Anemic patients with CKD stage 5D on hemodialysis and on a stable erythropoiesis-stimulating agent regimen received either two injections of 510 mg of ferumoxytol within 7 d (n = 114) or 200 mg elemental oral Iron daily for 21 d (n = 116). The primary efficacy endpoint was the change in hemoglobin from baseline to day 35. Safety was closely monitored. Results: Ferumoxytol resulted in a mean increase in hemoglobin of 1.02 ± 1.13 g/dl at day 35 compared with 0.46 ± 1.06 g/dl with oral Iron (P = 0.0002). Twice as many ferumoxytol-treated patients than oral Iron-treated patients achieved a ≥1 g/dl hemoglobin increase at day 35 (P = 0.0002). There was a greater mean increase in transferrin saturation (TSAT) with ferumoxytol compared with oral Iron at day 35 (P < 0.0001). The larger hemoglobin increase after ferumoxytol compared with oral Iron at day 35 persisted after adjustment for baseline hemoglobin, TSAT, and serum ferritin. Overall adverse event rates were comparable between groups. Conclusions: In patients on hemodialysis, rapid intravenous injection of 510 mg of ferumoxytol led to significantly greater hemoglobin increases compared with oral Iron, with comparable tolerability.
Dihua Wang - One of the best experts on this subject based on the ideXlab platform.
-
reduction mechanism and carbon content investigation for electrolytic Production of Iron from solid fe2o3 in molten k2co3 na2co3 using an inert anode
Journal of Electroanalytical Chemistry, 2013Co-Authors: Diyong Tang, Dihua Wang, Wei XiaoAbstract:Iron and oxygen was recently electrochemically prepared in molten Na2CO3-K2CO3 eutectic melt at 750 degrees C using a solid Iron oxide pellet cathode and a cheap Ni10Cu11 Fe alloy inert anode. This paper focuses to reveal the detailed reduction kinetics of solid Fe2O3 in the melt and also the effect of reduction potential on the carbon content in the Iron Product. The reduction mechanism was systematically investigated by cyclic voltammetric measurements, potentiostatic electrolysis combining with the composition and morphology analysis of the Products obtained at different potentials. It was found that the reduction of Fe2O3 involves three steps, with the formation of intermediate Products, viz., NaFe2O3 and NaFeO2. The influence of electrolysis voltage/potential on the carbon content in the Products was investigated by using both constant voltage and potentiostatic electrolysis under different conditions. The carbon content was found to be in the range of 0.035-0.76 wt.%, depending on the applied cathodic potential. The Iron-based Products with higher carbon content can be obtained upon electrolysis at a higher cell voltage or a more negative potential. The present results also demonstrated a controllable extraction of Fe-C steels with desired carbon content through an envIronmental friendly way. (C) 2012 Elsevier B.V. All rights reserved.
Cançado, Rodolfo Delfini - One of the best experts on this subject based on the ideXlab platform.
-
Intravenous ferric carboxymaltose for the treatment of Iron deficiency anemia
Associação Brasileira de Hematologia Hemoterapia e Terapia Celular. Published by Elsevier Editora Ltda., 2015Co-Authors: Friedrisch, João Ricardo, Cançado, Rodolfo DelfiniAbstract:AbstractNutritional Iron deficiency anemia is the most common deficiency disorder, affecting more than two billion people worldwide. Oral Iron supplementation is usually the first choice for the treatment of Iron deficiency anemia, but in many conditions, oral Iron is less than ideal mainly because of gastrointestinal adverse events and the long course needed to treat the disease and replenish body Iron stores. Intravenous Iron compounds consist of an Iron oxyhydroxide core, which is surrounded by a carbohydrate shell made of polymers such as dextran, sucrose or gluconate. The first Iron Product for intravenous use was the high molecular weight Iron dextran. However, dextran-containing intravenous Iron preparations are associated with an elevated risk of anaphylactic reactions, which made physicians reluctant to use intravenous Iron for the treatment of Iron deficiency anemia over many years. Intravenous ferric carboxymaltose is a stable complex with the advantage of being non-dextran-containing and a very low immunogenic potential and therefore not predisposed to anaphylactic reactions. Its properties permit the administration of large doses (15mg/kg; maximum of 1000mg/infusion) in a single and rapid session (15-minute infusion) without the requirement of a test dose. The purpose of this review is to discuss some pertinent issues in relation to the history, pharmacology, administration, efficacy, and safety profile of ferric carboxymaltose in the treatment of patients with Iron deficiency anemia
-
Intravenous ferric carboxymaltose for the treatment of Iron deficiency anemia
Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular, 2015Co-Authors: Friedrisch, João Ricardo, Cançado, Rodolfo DelfiniAbstract:ABSTRACT Nutritional Iron deficiency anemia is the most common deficiency disorder, affecting more than two billion people worldwide. Oral Iron supplementation is usually the first choice for the treatment of Iron deficiency anemia, but in many conditions, oral Iron is less than ideal mainly because of gastrointestinal adverse events and the long course needed to treat the disease and replenish body Iron stores. Intravenous Iron compounds consist of an Iron oxyhydroxide core, which is surrounded by a carbohydrate shell made of polymers such as dextran, sucrose or gluconate. The first Iron Product for intravenous use was the high molecular weight Iron dextran. However, dextran-containing intravenous Iron preparations are associated with an elevated risk of anaphylactic reactions, which made physicians reluctant to use intravenous Iron for the treatment of Iron deficiency anemia over many years. Intravenous ferric carboxymaltose is a stable complex with the advantage of being non- dextran-containing and a very low immunogenic potential and therefore not predisposed to anaphylactic reactions. Its properties permit the administration of large doses (15 mg/kg; maximum of 1000 mg/infusion) in a single and rapid session (15-minute infusion) without the requirement of a test dose. The purpose of this review is to discuss some pertinent issues in relation to the history, pharmacology, administration, efficacy, and safety profile of ferric carboxymaltose in the treatment of patients with Iron deficiency anemia